PMC:7200337 / 76477-76680 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T864","span":{"begin":64,"end":65},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T34653","span":{"begin":112,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A11739","pred":"chebi_id","subj":"T34653","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"}],"text":"At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2481","span":{"begin":75,"end":77},"obj":"Gene"},{"id":"2487","span":{"begin":51,"end":59},"obj":"Species"},{"id":"2492","span":{"begin":105,"end":110},"obj":"Chemical"},{"id":"2493","span":{"begin":112,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A2481","pred":"tao:has_database_id","subj":"2481","obj":"Gene:6999"},{"id":"A2487","pred":"tao:has_database_id","subj":"2487","obj":"Tax:9606"},{"id":"A2492","pred":"tao:has_database_id","subj":"2492","obj":"MESH:C558899"},{"id":"A2493","pred":"tao:has_database_id","subj":"2493","obj":"MESH:C086979"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups."}

{"project":"LitCovid-sentences","denotations":[{"id":"T432","span":{"begin":0,"end":203},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups."}